PertussisNCT04113655
2-year Follow-up After a Single Dose Acellular Pertussis Vaccination
An observational study of Pertussis, run by Mahidol University at 2 sites in Thailand.
Trial summary
In July 2015-November 2016, a phase II/III randomized, observer-blind,controlled study of two acellular Pertussis vaccines (aP standalone and TdaP combined vaccined) manufactured by BioNet-Asia Co., Ltd. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Pertussis
- What is being tested?
- Pertagen (aP BioNet), Boostagen (TdaP BioNet) and Adacel
- Type of treatment
- Vaccines, Injection or infusion
- How many people
- 180 participants
- Where
- 2 sitesThailand
- Study dates
- 20 Jun 2017to 31 Jul 2017
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: The target population for this study is the group of subjects who had received one dose of acellular pertussis based vaccine in TDA202 trial at Vaccine Trial Centre (VTC), Faculty of Tropical Medicine, Mahidol University and who had completed the study follow-up at 1 year after vaccination.
Who may be able to join
- Having participated in TDA202 study, received a single dose of one of the 3 study vaccines, and completed 1 year follow-up visit.
- Written informed consent is obtained for subjects aged ≥18 years, or written assent and written informed consent are obtained from subjects aged <18 years and from their parent/legal guardian, respectively, prior to study entry.
- Capable to comply with study procedures and willing to provide with a blood sample.
Who cannot join
- Received lived attenuated vaccine within 3 months prior to participating in this study.
- Received vaccines other than lived attenuated vaccine within 28 days prior to participating in this study.
- History of receiving blood or blood component or immunoglobulin within 3 months prior recruitment
- History of receiving immunosuppressive drugs or systemic corticosteroid (>0.5 mg/kg of prednisolone or equivalent for more than 14 days) within 3 months prior to recruitment.
- Received diphtheria or tetanus or pertussis vaccine within 1 year prior to inclusion in the present study.
Trial locations and contacts
2 sites in 1 country.
Thailand2 sites
Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, 420/6 Ratchawithi Road, Ratchathewi,
Bangkok, 10400
Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University,
Bangkok, 10400
About this study
Official title: Antibody Persistence at 2 Years After a Single Dose Vaccination of Acellular Pertussis Vaccines Among Thai Adolescents
In July 2015-November 2016, a phase II/III randomized, observer-blind,controlled study of two acellular Pertussis vaccines (aP standalone and TdaP combined vaccined) manufactured by BioNet-Asia Co., Ltd. (Bionet) and chemically-detoxified Adacel Tdap vaccine was conducted in Bangkok, Thailand in healthy subjects aged 12-17 years (Protocol No. TDA202; http://clinicaltrials.in.th; Study ID:TCTR20150703002). A total of 450 subjects were enrolled into the study at 2 study sites (Site No.1:Faculty of Medicine Siriraj Hospital; Site No.2:Vaccine Trial Centre (VTC), Faculty of Tropical Medicine, Mahidol University) with equal number of 225 subjects enrolled at each study site. During the study, the subjects had been randomized in a 1:1:1 ratio to received intramuscularly a booster dose (0.5 mL) of the study vaccines.
In this current study, persistence of pertussis antibodies induced by a booster dose of recombinant acellular Pertussis based vaccines (Pertagen and Boostagen) manufactured by Bionet will be evaluated and compared to the conventional chemically-detoxified Tdap vaccine (Adacel) at 2 years after previously immunized in the TDA202 study.
Read the detailed description
The study population will included all subjects who participated in the TDA202 study at the Vaccine Trial Centre (VTC), Faculty of Tropical Medicine, Mahidol University, Bangkok.
This is further follow-up from TDA202 clinical trial, which was completed on 29 November 2016. Target population for this study is the group of subjects who had received one dose of one of the three study vaccines in the TDA202 trial at site VTC and who had completed the study follow-up at 1-year after vaccination (223 subjects).
The subjects who had received a single dose of one of the 3 study vaccines and completed 1-year follow-up visit at Day 336±28 during the TDA202 study will be called for consent process at 2 years after vaccination based on Vaccination Date in TDA202 study within ±1 month window period. Subjects aged ≥ 18 years who have signed the written informed consent form or subjects aged < 18 years who have signed the assent form with their parent/legal guardian's given written informed consent will be screened for general health status and those who fulfill all inclusion and exclusion criteria will be enrolled into the study.
Once enrolled, blood sample (approximately 5 mL) will be taken from all subjects. After blood collection, vaccination with a licensed influenza vaccine will be offered to all subjects.Blood samples will be processed for serum separation and shipped to Bionet Human Serology Laboratory where immunogenicity testing (ELISA antibodies against tetanus, diphtheria, Pertussis Toxin (PT) and Filamentous hemagglutinin (FHA) and PT neutralizing antibody by Chinese Hamster Ovary (CHO cell assay) will be performed . ELISA testing to detect antibodies against tetanus, diphtheria, and pertussis antigens (PT and FHA) will be performed for all enrolled subjects while CHO cell assay to detect PT neutralizing antibody will be performed only in the same subset of 75 subjects (25 subjects in each vaccine group) who had been selected for PT neutralizing antIbody assessment in the previous TDA202 study.
Statistical analysis will be performed to evaluate antibody persistence at 2 years after one dose of each study vaccine given to subjects during the previous TDA202 study.
Data management and statistical analysis will be performed by Center of Excellence for Biomedical and Public Health Informatics (BIOPHICS), Bangkok, Thailand.
- Conditions
- Pertussis
- Being tested
- Pertagen (aP BioNet), Boostagen (TdaP BioNet), Adacel
- Keywords
- TDA202, acellular pertussis vaccine, antibody persistence at 2 years after vaccination, Pertagen, Boostagen, aP vaccine
- Medical subject headings
- Whooping Cough
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pertagen (aP BioNet)Biological
Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.
The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202.
Boostagen (TdaP BioNet)Biological
Boostagen (TdaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TdaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TDaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.
The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202.
AdacelBiological
Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.
The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202
| Study group | Role | What they receive |
|---|---|---|
| acellular pertussis vaccine | Antibody persistence at 2 years after a single dose vaccination of Pertagen (aP BioNet), Boostagen (TdaP BioNet) and Adacel (comparator vaccine) administered in parent protocol TDA202 Receives: Biological: Pertagen (aP BioNet); Biological: Boostagen (TdaP BioNet); Biological: Adacel |
What is being measured
The primary outcome is the main question the study is designed to answer.
Anti-PT GMTs (IU/mL) at 2 years after vaccination
Assessed by ELISA in all evaluable subjects by vaccine groups
Measured: 2 years after vaccination ± 1 month
Anti-FHA GMTs (IU/mL) at 2 years after vaccination
Assessed by ELISA in all evaluable subjects by vaccine groups
Measured: 2 years after vaccination ± 1 month
Anti-Tetanus GMTs (IU/mL) at 2 years after vaccination
Assessed by ELISA in all evaluable subjects by vaccine groups
Measured: 2 years after vaccination ± 1 month
Anti-Diphtheria GMTs (IU/mL) at 2 years after vaccination
Assessed by ELISA in all evaluable subjects by vaccine groups
Measured: 2 years after vaccination ± 1 month
Seroconversion rates of subjects with booster response in anti-PT antibody titers at Day 28 and 2 years after vaccination compared to baseline in all evaluable subjects by vaccine groups
Booster response:
- In initially seronegative subjects (baseline titer < 5 IU/mL), post-vaccination antibody concentrations ≥ 20 IU/mL;
- In initially seropositive subjects with baseline titer ≥ 5 IU/mL and < 20 IU/mL, an increase of at least 4 times (≥ 4-fold) the baseline titer;
- In initially seropositive subjects with baseline titer ≥ 20 IU/mL, an increase of at least 2 times (≥ 2-fold) the baseline titer
Measured: 2 years after vaccination ± 1 month
Seroconversion rates of subjects with booster response in anti-FHA antibody titers at Day 28 and 2 years after vaccination compared to baseline in all evaluable subjects by vaccine groups
Booster response:
- In initially seronegative subjects (baseline titer < 5 IU/mL), post-vaccination antibody concentrations ≥ 20 IU/mL;
- In initially seropositive subjects with baseline titer ≥ 5 IU/mL and < 20 IU/mL, an increase of at least 4 times (≥ 4-fold) the baseline titer;
- In initially seropositive subjects with baseline titer ≥ 20 IU/mL, an increase of at least 2 times (≥ 2-fold) the baseline titer
Measured: 2 years after vaccination ± 1 month
Seroconversion rates of subjects with > 0.1 IU/mL of anti-Tetanus at Day 28 and 2 years after vaccination compared to baseline in all evaluable subjects by vaccine groups
Assessed by ELISA
Measured: 2 years after vaccination ± 1 month
Seroconversion rates of subjects with > 0.1 IU/mL of anti-Diphtheria at Day 28 and 2 years after vaccination compared to baseline in all evaluable subjects by vaccine groups
Assessed by ELISA
Measured: 2 years after vaccination ± 1 month
PT neutralizing GMTs (IU/mL) at 2 year after vaccination
PT neutralizing antibody assessed by Chinese Hamster Ovary (CHO) in subset of each vaccine group
Measured: 2 years after vaccination ± 1 month
Seroconversion rate of PT neutralizing antibody increase ≥ 4-fold at 2 years after vaccination compared to baseline
PT neutralizing antibody assessed by Chinese Hamster Ovary (CHO) in subset of each vaccine group
Measured: 2 years after vaccination ± 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Oct 2019
- Study start20 Jun 2017
- Primary completion4 Jul 2017
- Study completion31 Jul 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for PertussisStudies of the same condition, open and under way.
- More trials run by Mahidol UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 180 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mahidol University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Punnee Pitisuttithum, Mahidol University
- Investigators
- Punnee Pitisutthithum, MD, Principal investigator, Mahidol University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04113655
- Sponsor's protocol ID
- TDA202 2 year follow-up
- Status last verified
- Oct 2019
- First submitted
- 1 Oct 2019
- Last updated
- 3 Oct 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Pitisuttithum P, Chokephaibulkit K, Sirivichayakul C, Sricharoenchai S, Dhitavat J, Pitisuthitham A, Phongsamart W, Boonnak K, Lapphra K, Sabmee Y, Wittawatmongkol O, Chauhan M, Wijagkanalan W, Hommalai G, Fortuna L, Chinwangso P, Poredi IK, van den Biggelaar AHJ, Pham HT, Viviani S. Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial. Lancet Infect Dis. 2018 Nov;18(11):1260-1268. doi: 10.1016/S1473-3099(18)30375-X. Epub 2018 Sep 25.
PubMed 30266329
Study at a glance
From the registry record, last updated by the sponsor on 3 Oct 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Antibody Persistence at 2 Years After a Single Dose Vaccination of Acellular Pertussis Vaccines Among Thai Adolescents
- ClinicalTrials.gov ID
- NCT04113655
- Acronym / sponsor ID
- TDA202 2 year follow-up
- Conditions
- Pertussis
- Keywords
- TDA202, acellular pertussis vaccine, antibody persistence at 2 years after vaccination, Pertagen, Boostagen, aP vaccine
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 180 participants (actual)
- Lead sponsor
- Mahidol UniversityUniversity, hospital or other
- Study start
- 20 Jun 2017 (actual)
- Primary completion
- 4 Jul 2017 (actual)
- Study completion
- 31 Jul 2017 (actual)
- First posted
- 3 Oct 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In July 2015-November 2016, a phase II/III randomized, observer-blind,controlled study of two acellular Pertussis vaccines (aP standalone and TdaP combined vaccined) manufactured by BioNet-Asia Co., Ltd. (Bionet) and chemically-detoxified Adacel Tdap vaccine was conducted in Bangkok, Thailand in healthy subjects aged 12-17 years (Protocol No. TDA202; http://clinicaltrials.in.th; Study ID:TCTR20150703002). A total of 450 subjects were enrolled into the study at 2 study sites (Site No.1:Faculty of Medicine Siriraj Hospital; Site No.2:Vaccine Trial Centre (VTC), Faculty of Tropical Medicine, Mahidol University) with equal number of 225 subjects enrolled at each study site. During the study, the subjects had been randomized in a 1:1:1 ratio to received intramuscularly a booster dose (0.5 mL) of the study vaccines.
In this current study, persistence of pertussis antibodies induced by a booster dose of recombinant acellular Pertussis based vaccines (Pertagen and Boostagen) manufactured by Bionet will be evaluated and compared to the conventional chemically-detoxified Tdap vaccine (Adacel) at 2 years after previously immunized in the TDA202 study.
Detailed description
The study population will included all subjects who participated in the TDA202 study at the Vaccine Trial Centre (VTC), Faculty of Tropical Medicine, Mahidol University, Bangkok.
This is further follow-up from TDA202 clinical trial, which was completed on 29 November 2016. Target population for this study is the group of subjects who had received one dose of one of the three study vaccines in the TDA202 trial at site VTC and who had completed the study follow-up at 1-year after vaccination (223 subjects).
The subjects who had received a single dose of one of the 3 study vaccines and completed 1-year follow-up visit at Day 336±28 during the TDA202 study will be called for consent process at 2 years after vaccination based on Vaccination Date in TDA202 study within ±1 month window period. Subjects aged ≥ 18 years who have signed the written informed consent form or subjects aged < 18 years who have signed the assent form with their parent/legal guardian's given written informed consent will be screened for general health status and those who fulfill all inclusion and exclusion criteria will be enrolled into the study.
Once enrolled, blood sample (approximately 5 mL) will be taken from all subjects. After blood collection, vaccination with a licensed influenza vaccine will be offered to all subjects.Blood samples will be processed for serum separation and shipped to Bionet Human Serology Laboratory where immunogenicity testing (ELISA antibodies against tetanus, diphtheria, Pertussis Toxin (PT) and Filamentous hemagglutinin (FHA) and PT neutralizing antibody by Chinese Hamster Ovary (CHO cell assay) will be performed . ELISA testing to detect antibodies against tetanus, diphtheria, and pertussis antigens (PT and FHA) will be performed for all enrolled subjects while CHO cell assay to detect PT neutralizing antibody will be performed only in the same subset of 75 subjects (25 subjects in each vaccine group) who had been selected for PT neutralizing antIbody assessment in the previous TDA202 study.
Statistical analysis will be performed to evaluate antibody persistence at 2 years after one dose of each study vaccine given to subjects during the previous TDA202 study.
Data management and statistical analysis will be performed by Center of Excellence for Biomedical and Public Health Informatics (BIOPHICS), Bangkok, Thailand.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| acellular pertussis vaccine | – | Biological: Pertagen (aP BioNet), Biological: Boostagen (TdaP BioNet), Biological: AdacelAntibody persistence at 2 years after a single dose vaccination of Pertagen (aP BioNet), Boostagen (TdaP BioNet) and Adacel (comparator vaccine) administered in parent protocol TDA202 |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The target population for this study is the group of subjects who had received one dose of acellular pertussis based vaccine in TDA202 trial at Vaccine Trial Centre (VTC), Faculty of Tropical Medicine, Mahidol University and who had completed the study follow-up at 1 year after vaccination.
Key inclusion criteria (3 listed)
- Having participated in TDA202 study, received a single dose of one of the 3 study vaccines, and completed 1 year follow-up visit.
- Written informed consent is obtained for subjects aged ≥18 years, or written assent and written informed consent are obtained from subjects aged <18 years and from their parent/legal guardian, respectively, prior to study entry.
- Capable to comply with study procedures and willing to provide with a blood sample.
Key exclusion criteria (5 listed)
- Received lived attenuated vaccine within 3 months prior to participating in this study.
- Received vaccines other than lived attenuated vaccine within 28 days prior to participating in this study.
- History of receiving blood or blood component or immunoglobulin within 3 months prior recruitment
- History of receiving immunosuppressive drugs or systemic corticosteroid (>0.5 mg/kg of prednisolone or equivalent for more than 14 days) within 3 months prior to recruitment.
- Received diphtheria or tetanus or pertussis vaccine within 1 year prior to inclusion in the present study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pertagen (aP BioNet)Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202. | Biological | acellular pertussis vaccine |
| Boostagen (TdaP BioNet)Boostagen (TdaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TdaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TDaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid. The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202. | Biological | acellular pertussis vaccine |
| AdacelComparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation. The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202 | Biological | acellular pertussis vaccine |
Primary outcome
Anti-PT GMTs (IU/mL) at 2 years after vaccination
Time frame: 2 years after vaccination ± 1 month
Assessed by ELISA in all evaluable subjects by vaccine groups
Anti-FHA GMTs (IU/mL) at 2 years after vaccination
Time frame: 2 years after vaccination ± 1 month
Assessed by ELISA in all evaluable subjects by vaccine groups
Anti-Tetanus GMTs (IU/mL) at 2 years after vaccination
Time frame: 2 years after vaccination ± 1 month
Assessed by ELISA in all evaluable subjects by vaccine groups
Anti-Diphtheria GMTs (IU/mL) at 2 years after vaccination
Time frame: 2 years after vaccination ± 1 month
Assessed by ELISA in all evaluable subjects by vaccine groups
Seroconversion rates of subjects with booster response in anti-PT antibody titers at Day 28 and 2 years after vaccination compared to baseline in all evaluable subjects by vaccine groups
Time frame: 2 years after vaccination ± 1 month
Booster response: * In initially seronegative subjects (baseline titer < 5 IU/mL), post-vaccination antibody concentrations ≥ 20 IU/mL; * In initially seropositive subjects with baseline titer ≥ 5 IU/mL and < 20 IU/mL, an increase of at least 4 times (≥ 4-fold) the baseline titer; * In initially seropositive subjects with baseline titer ≥ 20 IU/mL, an increase of at least 2 times (≥ 2-fold) the baseline titer
Seroconversion rates of subjects with booster response in anti-FHA antibody titers at Day 28 and 2 years after vaccination compared to baseline in all evaluable subjects by vaccine groups
Time frame: 2 years after vaccination ± 1 month
Booster response: * In initially seronegative subjects (baseline titer < 5 IU/mL), post-vaccination antibody concentrations ≥ 20 IU/mL; * In initially seropositive subjects with baseline titer ≥ 5 IU/mL and < 20 IU/mL, an increase of at least 4 times (≥ 4-fold) the baseline titer; * In initially seropositive subjects with baseline titer ≥ 20 IU/mL, an increase of at least 2 times (≥ 2-fold) the baseline titer
Seroconversion rates of subjects with > 0.1 IU/mL of anti-Tetanus at Day 28 and 2 years after vaccination compared to baseline in all evaluable subjects by vaccine groups
Time frame: 2 years after vaccination ± 1 month
Assessed by ELISA
Seroconversion rates of subjects with > 0.1 IU/mL of anti-Diphtheria at Day 28 and 2 years after vaccination compared to baseline in all evaluable subjects by vaccine groups
Time frame: 2 years after vaccination ± 1 month
Assessed by ELISA
PT neutralizing GMTs (IU/mL) at 2 year after vaccination
Time frame: 2 years after vaccination ± 1 month
PT neutralizing antibody assessed by Chinese Hamster Ovary (CHO) in subset of each vaccine group
Seroconversion rate of PT neutralizing antibody increase ≥ 4-fold at 2 years after vaccination compared to baseline
Time frame: 2 years after vaccination ± 1 month
PT neutralizing antibody assessed by Chinese Hamster Ovary (CHO) in subset of each vaccine group
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Oct 2019.
- Background: PubMed 30266329Pitisuttithum P, Chokephaibulkit K, Sirivichayakul C, Sricharoenchai S, Dhitavat J, Pitisuthitham A, Phongsamart W, Boonnak K, Lapphra K, Sabmee Y, Wittawatmongkol O, Chauhan M, Wijagkanalan W, Hommalai G, Fortuna L, Chinwangso P, Poredi IK, van den Biggelaar AHJ, Pham HT, Viviani S. Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial. Lancet Infect Dis. 2018 Nov;18(11):1260-1268. doi: 10.1016/S1473-3099(18)30375-X. Epub 2018 Sep 25.
- Individual participant dataSharing planned: Undecided
Related trials for Pertussis
RecruitingPhase 2
A Phase II Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)
Pertussis (Whooping Cough), Diphtheria
RecruitingPhase 1/2
A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed
Diphtheria, Pertussis
RecruitingPhase 4
Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy
RSV, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination
Not yet recruitingObservational study
Assessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the Ile-de-France Region
Vaccination Coverage Among Pregnant Women
Not yet recruitingPhase 1/2
Safety and Immunogenicity of a Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Recombinant Poliomyelitis and Haemophilus Influenzae Type b (Hib) Vaccine (SIIPL DTwP-HepB-rPV-Hib)
Diptheria Immunization, Tetanus Immunization
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Punnee Pitisutthithum, MD principal investigator
Mahidol University
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pertussis, run by Mahidol University at 2 sites in Thailand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Oct 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Anti-PT GMTs (IU/mL) at 2 years after vaccination (time frame: 2 years after vaccination ± 1 month). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04113655, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Oct 2019.